22
Biopharmaceutica l Quality Cynthia H Sarnoski PhD 28 th June 2012

Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

Embed Size (px)

Citation preview

Page 1: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

Biopharmaceutical Quality

Cynthia H Sarnoski PhD28th June 2012

Page 2: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

2

What is Quality?

Page 3: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

3

Quality

Quality is never an accident;

it is always the result of high intention,

sincere effort, intelligent direction and skillful

execution;it represents the wise choice of many alternatives.

~ William A. Foster ~

Page 4: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

4

Basis for Quality Requirements

Customer expectationsGood Business PracticeGood Science PracticeRegulatory conformance

Page 5: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

5

Regulatory Agencies

FDA (Food and Drug Administration)To promote/protect public health by helping safe/effective products reach the market in a timely way.

EMEA (European Agency for the Evaluation of Medicinal Products)To protect public health thru evaluation and supervision of

medicines

Other National Agencies (MHRA, IMB, ANVISA, etc.)

To ensure medicines sold/supplied to other countries are safe, efficacious and meet required quality.

Page 6: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

6

Requirements within the Code of Federal Regulations 21CFR 211.22 for the Quality Unit

Role of GQO

According to US regulations,

the Quality Unit

must act independently

of production/manufacturing

in executing it’s responsibilities.

Page 7: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

7

Current Good Manufacturing Practices 21CFR 211

Establish requirements for the manufacture of safe, effective, potent, pure and stable products.These include:Facilities, Equipment, Process, and Materials are appropriate for intended purpose.Appropriately skilled personnelManagement ControlsDocumented evidence

Page 8: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

8

Typical Quality Unit

Quality Control +Quality Assurance__________________Quality Unit

Page 9: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

9

Quality Unit Responsibilities

Approve or reject all Production MaterialsReview and approve allProcedures and SpecificationsValidation/Qualification documentsChange ControlsRegulatory SubmissionsEnsure systems/programs are established and maintained for:Adequate inspection, sampling, and testingIdentification of deviations, investigations and corrective actions/preventative actionsMany, many more . . . . .

Role of GQO

Page 10: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

10

Quality is maintained throughout the product life cycle…

Cell BanksRaw

MaterialsComponents

Cell Culture PurificationActive

SubstanceFinal

Product

<<<<<<<Quality Assurance + Quality Control >>>>>>>>

Page 11: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

11

Key Quality Processes

Quality Control

Product Disposition

Marketed Product Support

Page 12: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

12

Quality Control Sampling and Testing

● Raw Materials● Media● Components● Process materials● Water● Environment● In-Process● Cell banks● Bulk drug substance● Finished Product

Page 13: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

13

Laboratory Controls

Sample chain of custodyCompendial standardsValidated methodsReagent controlReference standardsEquipment ValidationEquipment CalibrationDocumentation

Page 14: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

14

Testing Requirements

Adventitious agent contamination controlViral, microbialPotencyPurityProcessStabilityCharacterizationIdentitySafetyComposition: excipientsForensics

Page 15: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

15

Drug Product Testing

E n v iro n m e n ta lM o n ito ring

E xc ip ie n ts

E n v irn m en ta lM o n ito ring

R a wM a te ria ls

E n v irn m en ta lM o n ito ring

R a wM a te ria ls

M e d iaC o m p o ne n ts

E n v iro n m e n ta lM o n io to ring

M e d iaC o m p o ne n ts

E n v iro n m e n ta lM o n io to ring

M e d iaC o m p o ne n ts

C e llB a nk

In p roce ssT e s ts

P ro du c tionC e lls

In P roce ssT e s ts

P ro ce ssM a te ria ls

F e rm e n ta tionIn te rm ed ia te

In P roce ssT e s ts

P ro ce ssM a te ria ls

P u rif ica tionIn te rm ed ia te

In P roce ssT e s ts

R e s in s P ro ce ssM a te ria ls

A c tiveS u bs tan ce

C o n ta in erC lo su res

In P roce ssT e s ts

D ru g P ro d u ct

Page 16: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

16

Product Disposition

Batch Record ReviewTest Record ReviewInvestigationsChange Controls

Page 17: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

17

Product Disposition continued

Key responsibilities at Product DispositionMarketing authorizationCompliance with cGMP’sUnderstanding impact of deviations --

quality, safety, efficacy

Engagement in quality systems supportingproduct manufacture and control

Understanding those deviations requiring regulatory action

Page 18: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

18

Marketed Product Support

● Stability●Cell banks●Active Substance●Final Drug Product●Annual Product ReviewsField Alerts & Biological Products Deviation Report (BPDRs) Product QualityInquiriesComplaintsAdverse Events

Page 19: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

19

Marketed Product Support continued

Inquiries A non-medical comment, question or request for

information such as product availability, temperature/stability, product expiry dating, dosing, product formulations/ingredients, chemical composition of componentry, etc.

Complaints A report regarding an alleged defect associated

with physical, chemical, microbiological, or other aspect of a product, component, or package.

Page 20: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

20

Marketed Product Support continued

Adverse Events

Any untoward, undesired or unplanned eventin the form of signs, symptoms, disease or

laboratoryor physiological observations occurring in a

personadministered a product

Page 21: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

21

Quality Personnel Competencies

Good science practicesProblem solvingGood analytical practicesGood documentation practicesEffective communication skillsVerbal and writtenDecision makingPursuit of “WHY?”

Page 22: Biopharmaceutical Quality Cynthia H Sarnoski PhD 28 th June 2012

22

Questions?